LKT Laboratories, Inc.

20(S)-Ginsenoside Rh2

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID G3453
CAS No. 78214-33-2
Chemical Name



Synonym 20S-GinsenosideRh2, 20S-protopanaxdiol-3-O-β-D- glucopyranoside, β-D-Glucopyranoside

Formula $C_{36}H_{62}O_8\ H_2O$
Formula Wt. 640.89
Melting Point
Purity ≥98%
Solubility Soluble in ethanol to 10 mM. Insoluble in water.

Bulk quanitites available upon request

Product ID	Size
G3453	1 mg
G3453	5 mg
G3453	10 mg
G3453	25 mg

Store Temp 4°C
Ship Temp Ambient

Description Ginsenoside Rh2 is a triterpene saponin found in *Panax* and exhibits anticancer chemotherapeutic, anti-metastatic, neuroprotective, cognition enhancing, anti-inflammatory, anti-osteoporotic, antioxidative, and anti-diabetic activities. Ginsenoside Rh2 inhibits aldose reductase and also decreases levels of ROS in keratinocytes. Ginsenoside Rh2 inhibits cell migration, decreases levels of matrix metalloproteinase 3 (MMP3), and increases recruitment of HDAC4 in liver carcinoma cells. In cellular and animal models of glioblastoma, ginsenoside Rh2 inhibits cell and tumor growth. Additionally, ginsenoside Rh2 improves learning and memory by decreasing levels of amyloid-β (Aβ) in animal models of Alzheimer's disease. In LPS-stimulated macrophages, this compound decreases the release of IL-1β, TNF-α, IL-6, PGE2, and NO and suppresses phosphorylation of p38 MAPK, ERK1/2, JAK, and NF-κB. Ginsenoside Rh2 inhibits osteoclastogenesis by suppressing RANKL-induced osteoclast differentiation in vitro and in vivo. This compound also induces β-cell proliferation by activating Akt and PDX-1, improves glucose tolerance, and increases insulin levels in animal models.

References

Fatmawati S, Ersam T, Yu H, et al. 20(S)-Ginsenoside Rh2 as aldose reductase inhibitor from Panax ginseng. Bioorg Med Chem Lett. 2014 Aug 12. [Epub ahead of print]. PMID: 25152999.

Shi Q, Li J, Feng Z, et al. Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: Recruiting histone deacetylase and inhibiting activator protein 1 transcription factors. Mol Med Rep. 2014 Jul 18. [Epub ahead of print]. PMID: 25051397.

Li S, Gao Y, Ma W, et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 2014 Jun;35(6):5593-8. PMID: 24557544.

Qiu J, Li W, Feng SH, et al. Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway. Genet Mol Res. 2014 May 9;13(2):3586-98. PMID: 24854439.

Yi PF, Bi WY, Shen HQ, et al. Inhibitory effects of sulfated 20(S)-ginsenoside Rh2 on the release of pro-inflammatory mediators in LPS-induced RAW 264.7 cells. Eur J Pharmacol. 2013 Jul 15;712(1-3):60-6. PMID: 23665488.

Choi WY, Lim HW, Lim CJ. Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes. J Pharm Pharmacol. 2013 Feb;65(2):310-6. PMID: 23278699.

He L, Lee J, Jang JH, et al. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.